Testing engineered immune cells to prevent colorectal cancer return

This trial is testing a new treatment called TROP2-CAR-NK cells combined with cetuximab (an antibody drug already used for colorectal cancer) for patients whose cancer appears to be gone on scans but who still have small traces of cancer DNA in their blood. These special immune cells are engineered in a laboratory to find and destroy remaining cancer cells. The study will first figure out the safest and most effective dose of the medication, then test it in a larger group to see if it can eliminate those cancer traces and prevent the cancer from coming back.

Even after surgery and chemotherapy, some colorectal cancer patients still have tiny amounts of cancer DNA circulating in their blood, which means there is a high risk the cancer will return. This trial exists to test whether engineered immune cells can eliminate those remaining traces before the cancer becomes active again.